Legend Biotech Corporation (LEGN) News

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) updates: Net trade sales of approximately $286 million...

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates...

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

SOMERSET, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year...

Form 144 - Report of proposed sale of securities